Teladoc Health (NYSE:TDOC) PT Raised to $205.00

Teladoc Health (NYSE:TDOC) had its price target raised by Stifel Nicolaus from $144.00 to $205.00 in a research note issued to investors on Thursday, BenzingaRatingsTable reports. The brokerage presently has a “hold” rating on the health services provider’s stock. Stifel Nicolaus’ price objective would indicate a potential downside of 13.73% from the company’s previous close.

Several other analysts have also issued reports on the stock. Robert W. Baird increased their price target on shares of Teladoc Health from $130.00 to $135.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 15th. Craig Hallum increased their price target on shares of Teladoc Health from $140.00 to $150.00 and gave the stock a “hold” rating in a research report on Thursday, April 30th. KeyCorp increased their price target on shares of Teladoc Health from $195.00 to $240.00 and gave the stock an “overweight” rating in a research report on Thursday. Deutsche Bank increased their price target on shares of Teladoc Health from $184.00 to $238.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, ValuEngine downgraded shares of Teladoc Health from a “buy” rating to a “hold” rating in a research note on Friday, May 1st. Fifteen analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $195.04.

Shares of NYSE:TDOC opened at $237.63 on Thursday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.14 and a current ratio of 6.14. The company’s 50 day moving average price is $207.13 and its two-hundred day moving average price is $158.76. Teladoc Health has a 12-month low of $54.58 and a 12-month high of $240.00.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, July 29th. The health services provider reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.11). The firm had revenue of $241.03 million for the quarter, compared to analyst estimates of $220.49 million. Teladoc Health had a negative return on equity of 10.23% and a negative net margin of 13.22%. The business’s revenue was up 85.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.41) EPS. As a group, sell-side analysts forecast that Teladoc Health will post -1.41 EPS for the current year.

In related news, SVP Andrew Turitz sold 2,778 shares of Teladoc Health stock in a transaction on Friday, June 19th. The shares were sold at an average price of $200.00, for a total transaction of $555,600.00. Following the completion of the transaction, the senior vice president now owns 6,793 shares of the company’s stock, valued at $1,358,600. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael Goldstein sold 8,000 shares of Teladoc Health stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $163.00, for a total transaction of $1,304,000.00. Following the transaction, the director now directly owns 8,000 shares of the company’s stock, valued at approximately $1,304,000. The disclosure for this sale can be found here. Insiders have sold 189,977 shares of company stock valued at $36,248,032 in the last three months. 3.42% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Baldwin Brothers Inc. MA grew its holdings in Teladoc Health by 2.9% in the second quarter. Baldwin Brothers Inc. MA now owns 2,820 shares of the health services provider’s stock worth $538,000 after purchasing an additional 80 shares during the period. Citizens Financial Group Inc RI grew its holdings in shares of Teladoc Health by 20.4% during the first quarter. Citizens Financial Group Inc RI now owns 489 shares of the health services provider’s stock valued at $76,000 after buying an additional 83 shares during the last quarter. Cypress Asset Management Inc. TX grew its holdings in shares of Teladoc Health by 1.2% during the second quarter. Cypress Asset Management Inc. TX now owns 7,040 shares of the health services provider’s stock valued at $1,344,000 after buying an additional 85 shares during the last quarter. Wealthstreet Investment Advisors LLC grew its holdings in shares of Teladoc Health by 1.5% during the first quarter. Wealthstreet Investment Advisors LLC now owns 6,752 shares of the health services provider’s stock valued at $1,047,000 after buying an additional 100 shares during the last quarter. Finally, Parallel Advisors LLC grew its holdings in shares of Teladoc Health by 2.3% during the second quarter. Parallel Advisors LLC now owns 4,517 shares of the health services provider’s stock valued at $862,000 after buying an additional 101 shares during the last quarter. 97.14% of the stock is owned by institutional investors and hedge funds.

About Teladoc Health

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Further Reading: How is an ETF different from a mutual fund?

Analyst Recommendations for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.